Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

Among patients with heart failure and a reduced ejection fraction, those who received the cardiac myosin activator omecamtiv mecarbil had a lower incidence of a composite of heart-failure events or cardiovascular death at a median of 22 months than those who received placebo.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-01, Vol.384 (2), p.105-116
Hauptverfasser:	Teerlink, John R, Diaz, Rafael, Felker, G. Michael, McMurray, John J.V, Metra, Marco, Solomon, Scott D, Adams, Kirkwood F, Anand, Inder, Arias-Mendoza, Alexandra, Biering-Sørensen, Tor, Böhm, Michael, Bonderman, Diana, Cleland, John G.F, Corbalan, Ramon, Crespo-Leiro, Maria G, Dahlström, Ulf, Echeverria, Luis E, Fang, James C, Filippatos, Gerasimos, Fonseca, Cândida, Goncalvesova, Eva, Goudev, Assen R, Howlett, Jonathan G, Lanfear, David E, Li, Jing, Lund, Mayanna, Macdonald, Peter, Mareev, Viacheslav, Momomura, Shin-ichi, O’Meara, Eileen, Parkhomenko, Alexander, Ponikowski, Piotr, Ramires, Felix J.A, Serpytis, Pranas, Sliwa, Karen, Spinar, Jindrich, Suter, Thomas M, Tomcsanyi, Janos, Vandekerckhove, Hans, Vinereanu, Dragos, Voors, Adriaan A, Yilmaz, Mehmet B, Zannad, Faiez, Sharpsten, Lucie, Legg, Jason C, Varin, Claire, Honarpour, Narimon, Abbasi, Siddique A, Malik, Fady I, Kurtz, Christopher E
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Angina pectoris Arrhythmia Brain natriuretic peptide Calcium-binding protein Cardiac Myosins - drug effects Cardiac Myosins - metabolism Cardiology and cardiovascular system Cardiomyopathy Cardiotonic Agents - adverse effects Cardiotonic Agents - pharmacology Cardiotonic Agents - therapeutic use Cardiovascular Diseases - mortality Clinical medicine Congestive heart failure Design Ejection fraction Female Heart attacks Heart failure Heart Failure, Systolic - drug therapy Heart Failure, Systolic - metabolism Heart Failure, Systolic - physiopathology Hospitalization Human health and pathology Humans Ischemia Life Sciences Male Middle Aged Myocardial Contraction - drug effects Myosin Patient safety Peptides Placebos Statistical analysis Stroke Volume Troponin Troponin I Urea - adverse effects Urea - analogs & derivatives Urea - pharmacology Urea - therapeutic use Ventricle
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Among patients with heart failure and a reduced ejection fraction, those who received the cardiac myosin activator omecamtiv mecarbil had a lower incidence of a composite of heart-failure events or cardiovascular death at a median of 22 months than those who received placebo.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2025797